22.05.2017 22:48:00
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
NEW YORK, May 22, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On May 22, 2017, Amgen disclosed that its osteoporosis medicine Evenity raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by the Company, a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, compared to those who took an older approved medicine.
On this news, Amgen's share price has fallen as much as $3.42 or 2.20%, during intraday trading on May 22, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-amgen-inc--amgn-300461711.html
SOURCE Pomerantz LLP
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amgen Inc.mehr Nachrichten
06.01.25 |
Dow Jones 30 Industrial-Titel Amgen-Aktie: So viel Verlust hätte ein Investment in Amgen von vor einem Jahr bedeutet (finanzen.at) | |
30.12.24 |
Dow Jones 30 Industrial-Titel Amgen-Aktie: So viel Gewinn hätte ein Amgen-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
26.12.24 |
Gute Stimmung in New York: Dow Jones zum Handelsende auf grünem Terrain (finanzen.at) | |
24.12.24 |
Optimismus in New York: Dow Jones zum Ende des Dienstagshandels auf grünem Terrain (finanzen.at) | |
24.12.24 |
Handel in New York: Dow Jones bewegt sich im Plus (finanzen.at) | |
24.12.24 |
Börse New York: So steht der Dow Jones mittags (finanzen.at) | |
24.12.24 |
Börse New York: Dow Jones zeigt sich zum Start fester (finanzen.at) | |
24.12.24 |
Pluszeichen in New York: NASDAQ 100 zum Handelsstart im Plus (finanzen.at) |
Analysen zu Amgen Inc.mehr Analysen
Aktien in diesem Artikel
Amgen Inc. | 253,15 | 1,02% |